Last Name



This is a "connection" page, showing publications co-authored by Sefer Gezer and Parameswaran Venugopal.

Connection Strength
  1. Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Clin Adv Hematol Oncol. 2008 Aug; 6(8):587-90.
    View in: PubMed
    Score: 0.091
  2. Rao S, Warrior S, Luo S, Gezer S, Venugopal P, Jain S. Impact of blood type on thrombosis and disease severity in adult COVID-19 patients. Thromb Res. 2021 10; 206:145-147.
    View in: PubMed
    Score: 0.057
  3. Warrior S, Behrens E, Thomas J, Gezer S, Venugopal P, Jain S. Prevention of Thromboembolic Events in Patients with COVID-19. TH Open. 2021 Jul; 5(3):e415-e419.
    View in: PubMed
    Score: 0.056
  4. Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G. Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.
    View in: PubMed
    Score: 0.017
  5. Raza A, Qawi H, Andric T, Dar S, Lisak L, Huang RW, Venugopal P, Gezer S, Gregory SA, Hsu WT, Loew J, Robin E, Rifkin S, Shah R, Divgi A, Taylor R, Grosset A. Pentoxifylline, Ciprofloxacin and Dexamethasone Improve the Ineffective Hematopoiesis in Myelodysplastic Syndrome Patients; Malignancy. Hematology. 2000; 5(4):275-284.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.